All News
Do We Stop or Continue Treatment?
Remission had been a dream, an elusive concept. But then, with the introduction of biologics, conventional synthetic and targeted synthetic DMARDS, patients are able to live longer and with a better quality of life. While these therapeutics have been helpful, they are expensive and carry potential side effects. The big question looms: Do we stop or continue treatment?
Read Article
JAKi and TYK2i: What to use and when?
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Read Article
Difficult toTreat PsA: Mainly Difficult to Define!
Dr. Aurelie Najm reports on abstract 0777 from the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/mqjhkfJ39B https://t.co/mdE8IrG27T
Dr. John Cush RheumNow ( View Tweet)
Reduction of AxSpa-Associated Acute Anterior Uveitis with Certolizumab
Acute anterior uveitis (AAU) is the most common extra-musculoskeletal manifestation in axial spondyloarthritis (axSpA), affecting up to 50% of patients in some age groups.
https://t.co/HpKk0kUWrb https://t.co/mdaRpVeYI2
Dr. John Cush RheumNow ( View Tweet)
Effective Treatments for Rheumatoid Arthritis ILD
The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence.
https://t.co/OWf6Ip2gEw https://t.co/B6zGtNti3t
Dr. John Cush RheumNow ( View Tweet)
Day 2 Report - ACR Plenaries: Changing the Practice of Rheumatology
https://t.co/SBFbA40cWu https://t.co/cvbtr2EcJD
Dr. John Cush RheumNow ( View Tweet)
Watch: Lupus Nephritis Therapy Paradigm Shift
Dr. Yuz Yusof reporting on abstract 0782 at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/m8SgtnVd95 https://t.co/cSexK2PCb5
Dr. John Cush RheumNow ( View Tweet)
IV Secukinumab for AxSpa
The FDA recently announced approval for intravenous secukinumab (Cosentyx) for adults with psoriatic arthritis, ankylosing spondylitis, and non-radiographic spondylitis.
https://t.co/JhOvPIXOMN https://t.co/GoV62NjSmf
Dr. John Cush RheumNow ( View Tweet)
How early is early in psoriatic arthritis?
Is there a window of opportunity for treatment in PsA to ensure optimal outcomes?
https://t.co/VkfQZpbtKA https://t.co/o2Vf9vRo9s
Dr. John Cush RheumNow ( View Tweet)
Cancer and TNF inhibitors
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions
https://t.co/fRAkAQ3tw8 https://t.co/Rs8ODYns2t
Dr. John Cush RheumNow ( View Tweet)
Watch: SpA Insights: New Therapies
https://t.co/fkFYpEnDoX https://t.co/bcVJfl2un2
Dr. John Cush RheumNow ( View Tweet)
#ACRbest Abstracts – Day 2
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract reports from Monday, 11/13 at #ACR23.
https://t.co/qc1PxBKmow https://t.co/leaXyuS2UF
Dr. John Cush RheumNow ( View Tweet)
Lupus Topic Panel
Featuring panelists Dr. Kathryn Dao, Eric Dein and Sheila Reyes, discussing the best and most interesting lupus studies presented at #ACR23.
https://t.co/4lZmEBH8or https://t.co/L1ZTNeMFWr
Links:
Dr. John Cush RheumNow ( View Tweet)
Methotrexate: shall we split up?
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
https://t.co/yxvI9Q0B9m https://t.co/MxPQ4DAGsj
Dr. John Cush RheumNow ( View Tweet)
Maintain Vigilance for CV Risk Postpartum in Autoimmune Diseases
Pregnant women with ARDs and APS face significantly increased risks of CVEs. This increased risk is often attributed to ARDs, its medications or comorbidities associated with it.
https://t.co/A2Keo8fH4p https://t.co/oHIYNNlzUU
Dr. John Cush RheumNow ( View Tweet)
#ACR23 BEST Abstracts from San Diego – Day 1
From hundreds of online presentations, the poster floor and the plenary podium, here are some of the best abstracts from 11/12/23. You can spot these on Twitter by looking for the (#ACRbest) hashtag.
https://t.co/hmSNMFuwAY https://t.co/1X89oE8Iet
Dr. John Cush RheumNow ( View Tweet)
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/shb8tpDut4 https://t.co/xLn36Yg9fn
Dr. John Cush RheumNow ( View Tweet)
RHEUM Survey Question: Your choice of a biologic in patients with SpA is mostly influenced by? Click here to answer: https://t.co/zevKhcDPjz
Dr. John Cush RheumNow ( View Tweet)
Watch: Ultrasound for PsA Stratification: Are We There Yet?
Dr. Aurelie Najm reports live from #ACR23
https://t.co/TeeBHl2LlU https://t.co/ObFtaJsTWp
Dr. John Cush RheumNow ( View Tweet)
New Biomarkers and Therapeutics Show Potential in Still's Disease
AOSD is a rare complex, sporadic, systemic autoinflammatory disease similar to sJIA characterized by sustained fever, salmon-colored rash, and arthritis
https://t.co/cGBBHsBdK7 https://t.co/a0EwBiTJSu
Dr. John Cush RheumNow ( View Tweet)